Skip to main content

Table 3 Base-case results

From: Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan

Strategy

Cost JPY (USD)

Incrmental Cost JPY (USD)

QALY

Incremental QALY

ICER JPY/QALY (USD/QALY)

PALO regimen

30,348 (270.55)

10,455 (93.21)

0.009598

0.000645208

16,204,591 (144,465)

GRA regimen

19,893 (177.35)

 

0.008952

  
  1. JPY Japanese yen, QALY Quality-adjusted life year, ICER Incremental cost-effectiveness ratio. Exchange rate, 1 USD = 112.17 JPY
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us